ClinicalTrials.gg
CompletedNCT00052442Updated Aug 25, 2021Results posted

10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

A Phase 1/2 interventional study of pralatrexate in Lymphoma, sponsored by Spectrum Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-25.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,909 studies in Lymphoma with a site in United States — 161 open to participants now, 288 under way, 15 of them phase 3. Lymphoma · United States.

Enrollment
407th of 1,594
72 · median 36
Started
2002
with 62 others
Phase 1/2
218 of 1,909
22 open now
Registered
371st of 1,909
by date

Among the 1,909 studies in Lymphoma with a site in United States, this one is the 407th largest by enrollment of the 1,594 interventional ones that give a count, is one of 63 that started in 2002, is one of 218 in phase 1/2, and was the 371st registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

161 of the 1,909 studies in Lymphoma with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,909 studies in Lymphoma with a site in United States, or all of them as a file.
02

Study summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or Hodgkin's lymphoma.

Read the detailed description

OBJECTIVES:

  • Determine the efficacy of 10-propargyl-10-deazaaminopterin, in terms of objective response rate, duration of response, and time to disease progression, in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma or Hodgkin's lymphoma.
  • Determine the impact of pharmacokinetics on toxicity and drug elimination in patients treated with this drug.
  • Determine the toxicity of this drug in these patients.
  • Determine the effect of prior chemotherapy response duration on duration of response in patients treated with this drug.
  • Correlate, if possible, the pharmacodynamics (area under the curve) of this drug with tumor response and toxicity (mucositis) in these patients.
  • Correlate, if possible, intraerythrocytic folate or homocysteine levels with severity of mucositis in patients treated with this drug.
  • Determine whether levels of the RFC-1 folate transporter, folylpolyglutamate synthetase, and folylpolyglutamate hydrolase are markers of response in patients treated with this drug.

OUTLINE: This is an open-label study.

Patients receive 10-propargyl-10-deazaaminopterin IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) may receive 2 additional courses beyond the CR.

PROJECTED ACCRUAL: A total of 39-72 patients (12-35 for cohort 1 and 17-37 for cohort 2) will be accrued for this study within 10-36 months.

03

Conditions studied

  • Lymphoma

Keywords

  • recurrent adult diffuse large cell lymphoma
  • recurrent adult diffuse mixed cell lymphoma
  • recurrent adult Burkitt lymphoma
  • recurrent adult immunoblastic large cell lymphoma
  • recurrent adult lymphoblastic lymphoma
  • recurrent mantle cell lymphoma
  • recurrent adult Hodgkin lymphoma
  • recurrent grade 3 follicular lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • confirmed Hodgkin's lymphoma or, using the World Health Organization (WHO) classification, aggressive non-Hodgkin's lymphoma including:

    • Large B- or T-cell lymphomas (including transformed lymphomas)
    • Mantle cell lymphoma
    • Immunoblastic lymphoma
  • At least 1 unidimensionally

    • At least 2 centimeter (cm) by conventional techniques OR
    • At least 1 cm by spiral computerized tomography (CT) scan
    • Lymph nodes no greater than 1 cm in the short axis are considered normal
  • disease after chemotherapy
  • Cohort 1:

    • No more than 3 prior conventional cytotoxic chemotherapy regimens
    • Must have had at least a partial response (PR) lasting no more than 6 months or refractory disease
    • Patients with disease refractory to or relapsed less than 100 days from peripheral blood stem cell (PBSC) transplantation are not eligible
  • Cohort 2:

    • No limit on prior treatment
    • Must have had at least a PR to the last therapy lasting at least 6 months
    • Patients who have received high-dose chemotherapy as part of peripheral blood stem cells (PBSC) transplantation are eligible if relapse occurred at least 100 days after transplantation
  • No pleural effusions or ascites
  • No active brain or

    • Treated Central nervous system (CNS) disease allowed

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • 70-100%

  • Not specified

Hematopoietic

  • greater than 1,000/mm\^3
  • count greater than 75,000/mm\^3
  • at least 10 g/dL

Hepatic

  • less than 1.5 times (ULN)
  • /alanine aminotransferase (AST/ALT) no greater than 2.5 times ULN (4 times ULN if liver involvement)
  • Alkaline phosphatase no greater than 5 times ULN

Renal

  • Creatinine no greater than 1.5 mg/dL OR
  • at least 50 mL/min

Cardiovascular

  • No symptomatic congestive heart failure
  • No class III or IV heart disease
  • No unstable angina pectoris
  • No cardiac arrhythmia
  • No myocardial infarction, cerebrovascular accident, or within the past 6 months
  • No history of orthostatic hypotension
  • No evidence of acute ischemia or significant conduction abnormality (e.g., bifascicular block or 2nd or 3rd degree atrioventricular blocks)
  • No uncontrolled hypertension requiring active manipulation of antihypertensive medications
  • No grade III or IV edema

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective
  • No ongoing or active infection

    • Febrile episodes up to 38.5° Celsius without signs of active infection allowed
  • No other concurrent active cancer
  • No other concurrent serious medical illness
  • No psychiatric illness or social situation that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics
  • At least 3 months since prior monoclonal antibody therapy (e.g., rituximab)

Chemotherapy

  • See Disease Characterisitics
  • At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered

Endocrine therapy

  • At least 7 days since prior
  • No concurrent steroids

Radiotherapy

  • See Disease Characteristics
  • At least 4 weeks since prior radiotherapy and recovered

Surgery

  • More than 4 weeks since prior major surgery

Other

  • No prior antifolates
  • No concurrent folic acid supplementation
  • No other concurrent agents
  • No concurrent combination antiretroviral therapy for (HIV)-positive patients
  • No other concurrent investigational or commercial agents or therapies with the intent to treat the
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    135 mg/m^2 Pralatrexate 1/2 weeks

    Pralatrexate (PDX) 135 mg/m\^2 administered as an intravenous (IV) infusion over one hour into a side arm of a running intravenous infusion of normal saline for 1/2 weeks.

    Drug: pralatrexate

  • Experimental
    30 mg/m^2 Pralatrexate 3/4 weeks

    PDX 30 mg/m\^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 3/4 weeks.

    Drug: pralatrexate

  • Experimental
    30 mg/m^2 Pralatrexate 6/7 weeks

    PDX 30 mg/m\^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.

    Drug: pralatrexate

  • Experimental
    45 mg/m^2 Pralatrexate 6/7 weeks

    PDX 45 mg/m\^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.

    Drug: pralatrexate

  • Experimental
    270 mg/m^2 Pralatrexate 2/4 weeks

    PDX (270 mg/m\^2) administered as an IV bolus over 3-5 minutes into a side arm of a running intravenous infusion of normal saline for 2/4 weeks.

    Drug: pralatrexate

Interventions

  • Also known as: Folotyn, 10-Propargyl-10-Deazaaminopterin (PDX)

06

What researchers measure

Primary outcomes

  1. Response Rate

    Per Response Evaluation Criteria in T-cell and B-cell Lymphoma for target lesions and assessed using computerized tomography (CT) and or Positron emission tomography CT (PET CT) by local investigators: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=50% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: 3 weeks

Secondary outcomes

  1. Toxicities of Pralatrexate

    Adverse events; number of patients with at least one adverse events reported.

    Time frame: 3 weeks

07

Results

Posted Aug 25, 2021
Limitations and caveats
Study completed

Participant flow

Participant flow — Overall Study
Milestone135 mg/m^2 Pralatrexate 1/2 Weeks30 mg/m^2 Pralatrexate 3/4 Weeks30 mg/m^2 Pralatrexate 6/7 Weeks45 mg/m^2 Pralatrexate 6/7 Weeks270 mg/m^2 Pralatrexate 2/4 Weeks
Started163271115
Completed163271115
Not completed00000

Outcome measures

PrimaryResponse Rate

Per Response Evaluation Criteria in T-cell and B-cell Lymphoma for target lesions and assessed using computerized tomography (CT) and or Positron emission tomography CT (PET CT) by local investigators: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=50% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
3 weeks
Reported as:
Count of participants · Participants
Response Rate
Participants135 mg/m^2 Pralatrexate 1/2 Weeks30 mg/m^2 Pralatrexate 3/4 Weeks30 mg/m^2 Pralatrexate 6/7 Weeks45 mg/m^2 Pralatrexate 6/7 Weeks270 mg/m^2 Pralatrexate 2/4 Weeks
Response Rate153271115
SecondaryToxicities of Pralatrexate

Adverse events; number of patients with at least one adverse events reported.

Time frame:
3 weeks
Reported as:
Count of participants · Participants
Toxicities of Pralatrexate
Participants135 mg/m^2 Pralatrexate 1/2 Weeks30 mg/m^2 Pralatrexate 3/4 Weeks30 mg/m^2 Pralatrexate 6/7 Weeks45 mg/m^2 Pralatrexate 6/7 Weeks270 mg/m^2 Pralatrexate 2/4 Weeks
Toxicities of Pralatrexate163271115

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
135 mg/m^2 Pralatrexate 1/2 Weeks—8/16 (50%)8/16 (50%)
30 mg/m^2 Pralatrexate 3/4 Weeks—1/3 (33.3%)2/3 (66.7%)
30 mg/m^2 Pralatrexate 6/7 Weeks—15/27 (55.6%)12/27 (44.4%)
45 mg/m^2 Pralatrexate 6/7 Weeks—10/11 (90.9%)1/11 (9.1%)
270 mg/m^2 Pralatrexate 2/4 Weeks—10/15 (66.7%)5/15 (33.3%)
Most frequent serious events
Most frequent serious events
Event135 mg/m^2 Pralatrexate 1/2 Weeks30 mg/m^2 Pralatrexate 3/4 Weeks30 mg/m^2 Pralatrexate 6/7 Weeks45 mg/m^2 Pralatrexate 6/7 Weeks270 mg/m^2 Pralatrexate 2/4 Weeks
StomatitisGastrointestinal disorders6/160/33/273/113/15
Neutropenia & ThrombocytopeniaBlood and lymphatic system disorders0/161/32/274/112/15
General DisordersGeneral disorders0/160/36/270/111/15
VomittingGastrointestinal disorders0/160/33/271/112/15
PharyngitisInfections and infestations2/160/30/271/110/15
Abdominal painGastrointestinal disorders0/160/30/271/111/15
Pleural EffusionRespiratory, thoracic and mediastinal disorders0/160/31/270/111/15
Most frequent other events
Most frequent other events
Event135 mg/m^2 Pralatrexate 1/2 Weeks30 mg/m^2 Pralatrexate 3/4 Weeks30 mg/m^2 Pralatrexate 6/7 Weeks45 mg/m^2 Pralatrexate 6/7 Weeks270 mg/m^2 Pralatrexate 2/4 Weeks
NauseaGastrointestinal disorders8/162/312/271/115/15

Baseline characteristics

Safety analysis population included all patients with at least one dose of pralatrexate.

Age, Continuous
Age, Continuous(years)135 mg/m2 Pralatrexate 1/2 Weeks30 mg/m2 Pralatrexate 3/4 Weeks30 mg/m2 Pralatrexate 6/7 Weeks45 mg/m2 Pralatrexate 6/7 Weeks270 mg/m2 Pralatrexate 2/4 WeeksTotal
Mean49.3 ± 16.154.3 ± 14.455.7 ± 16.552.7 ± 11.457.1 ± 15.154.1 ± 15.2
Sex: Female, Male
Sex: Female, Male(Participants)135 mg/m2 Pralatrexate 1/2 Weeks30 mg/m2 Pralatrexate 3/4 Weeks30 mg/m2 Pralatrexate 6/7 Weeks45 mg/m2 Pralatrexate 6/7 Weeks270 mg/m2 Pralatrexate 2/4 WeeksTotal
Female42107528
Male1211741044
Race (NIH/OMB)
Race (NIH/OMB)(Participants)135 mg/m2 Pralatrexate 1/2 Weeks30 mg/m2 Pralatrexate 3/4 Weeks30 mg/m2 Pralatrexate 6/7 Weeks45 mg/m2 Pralatrexate 6/7 Weeks270 mg/m2 Pralatrexate 2/4 WeeksTotal
American Indian or Alaska Native000000
Asian112206
Native Hawaiian or Other Pacific Islander000000
Black or African American2132311
White100215945
More than one race000000
Unknown or Not Reported3112310
08

Study locations

1 site
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
09

References and documents

Publications

  • O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, Neylon E, Mastrella J, Hamelers R, Macgregor-Cortelli B, Patterson M, Seshan VE, Sirotnak F, Fleisher M, Mould DR, Saunders M, Zelenetz AD. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009 Sep 10;27(26):4357-64. doi: 10.1200/JCO.2008.20.8470. Epub 2009 Aug 3. PubMed 19652067 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2002, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2021, 12 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2003
First posted
Jan 27, 2003
Start
Aug 2002
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Aug 25, 2021
Last update
Aug 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00052442
Responsible party
Sponsor
First posted
Jan 27, 2003
Start date
Aug 2002
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Aug 25, 2021
Last update
Aug 25, 2021

Study contacts

Owen A. O'Connor, MD, PhD
study chair · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pralatrexate

Start the discussion